-
Roth Remains Positive on Pharmacyclics (PCYC) Following Imbruvica Update; Maintains 'Buy' Rating
-
Roth Comments on Pharmacyclics (PCYC) Following Publication on New Imbruvica Data
-
Roth Boosts PT on TG Therapeutics (TGTX) to $33 on Strong ASH Showing, Buyout Prospects
-
Pharmacyclics (PCYC) Impresses at ASH; KOLs Excited About Prospects for Imbruvica - Roth Capital
-
Roth Boosts PT on Pharmacyclics (PCYC) to $188; Imbruvica Continues to Gain Traction
-
New Pharmacyclics (PCYC) Collaboration Further Validates Imbruvica; Roth Boosts PT to $185
-
Roth Sees 'Significant' and 'Impressive' Cost Efficiencies in TG Therapeutics' (TGTX) CLL Combo Phase 3
-
Roth Capital Comments on Pharmacyclics (PCYC) Following Expanded IMBRUVICA Coverage; Affirms 'Buy' Rating
-
Roth Positive on Pharmacyclics (PCYC) Following CHMP Recommendation of Imbruvica
-
Roth Keeps Pharmacyclics (PCYC) at 'Buy'; Imbruvica sNDA Selected for Priority Review by FDA
-
Pharmacyclics (PCYC) KOL Event at ASCO Impresses Physicians; Roth Keeps at 'Buy'
-
Roth Keeps Pharmacyclics (PCYC) at Buy; Still Positive on Imbruvica Following Phase III RESONTAE
-
Pharmacyclics (PCYC) Story Unchanged Following Q1 Report; Roth Reiterates at 'Buy'
-
Pharmacyclics' (PCYC) IMBRUVICA Should Get Full Approval Before End of 2014; Roth Keeps at 'Buy'
-
Pharmacyclics' (PCYC) IMBRUVICA Drives Strong Q4 Results; Roth Boosts PT to $183
-
Pharmacyclics (PCYC) PT Raised to $183 at Roth Capital
-
Roth Capital Boosts PT on Pharmacyclics (PCYC) to $166; Strong IMBRUVICA Sales Ramp Expected
-
Pharmacyclics (PCYC) Target Raised to $144 at Roth Capital
-
Notable Analyst Rating Changes 08/20: (ROST) (PB) (STO) Upgraded; (STEM) (STX) (PCYC) Downgraded
-
Roth Capital Downgrades Pharmacyclics (PCYC) to Neutral
-
Roth Capital Initiates Coverage on Pharmacyclics (PCYC) with a Buy

